|Parkinsonís Institute and Clinical Center partners with CENTOGENE to characterize Parkinsonís patients with targeted gene panel|
|Published Thursday, January 12, 2017 9:00 am|
For the first time, ever, the Parkinson’s Institute and Clinical Center and CENTOGENE have entered into a collaboration aimed at genetic screening of a large cohort of Parkinson’s patients in the US. Now, individual patients will be screened using a large customized panel carefully selected to identify pathophysiological relevant genetic variants for the development and treatment of Parkinson’s disease.
“This genetic screening will not only help provide actionable decisions for treating physicians but also the knowledge obtained will provide further insights for pharmaceutical and biotech companies conducting research in novel treatments for this debilitating disease,” says Dr. Carrolee Barlow, CEO, Parkinson’s Institute and Clinical Center.